SCHEMBL16239178

SCHEMBL16239178

Cc1cccc(C(=O)Nc2ccc(N3C(=O)CC(=O)Nc4c(C)cccc43)cc2)c1C

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 5/20 0.50
MAPT P10636 4/20 0.42
ALDH1A1 P00352 3/20 0.42
GAA P10253 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
AVPR2 P30518 1/20 0.39
AVPR1A P37288 1/20 0.39
GRM5 P41594 1/20 0.39
POLB P06746 1/20 0.39
CRHBP P24387 1/20 0.39
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39
CRHR2 Q13324 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16239078 0.88 P2RX4 (0.69) P2RX4
SCHEMBL30297388 0.88 P2RX4 (0.69) P2RX4
SCHEMBL16239127 0.84 P2RX4 (0.42) P2RX4MAPTALDH1A1GAANPC1
SCHEMBL16267449 0.82 P2RX4 (0.54) P2RX4MAPTALDH1A1GAANPC1
SCHEMBL16239032 0.81 CREBBP (0.44) P2RX4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL16239010 0.81 P2RX4 (0.49) P2RX4MAPTRAB9A
SCHEMBL16239170 0.81 P2RX4 (0.72) P2RX4MAPTALDH1A1GAANPC1
SCHEMBL30229672 0.81 P2RX4 (0.72) P2RX4MAPTALDH1A1GAANPC1
SCHEMBL16239121 0.79 P2RX4 (0.49) P2RX4MAPTALDH1A1GAANPC1
SCHEMBL16238983 0.78 P2RX4 (0.57) P2RX4MAPTTDP1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260000678-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION TAKASAKI UNIV OF HEALTH AND WELFARE (JP) 2026-01-01 US claimed
US-20250375456-A1 AGENT FOR PREVENTING OR TREATING RESPIRATORY DISEASE NIPPON CHEMIPHAR CO (JP) 2025-12-11 US claimed
US-20250241927-A1 MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN NIPPON CHEMIPHAR CO (JP) 2025-07-31 US claimed
EP-4501357-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS Takasaki University of Health and Welfare (JP) 2025-02-05 EP claimed
CN-119233829-A Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy 学校法人高崎健康福祉大学 2024-12-31 CN claimed
WO-2024177158-A1 SOLID DISPERSION OF COMPOUND HAVING P2X4 RECEPTOR ANTAGONISM 日本ケミファ株式会社 2024-08-29 WO claimed
EP-4410310-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR RESPIRATORY DISEASES Nippon Chemiphar Co., Ltd. (JP) 2024-08-07 EP claimed
EP-4408432-A1 MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN Nippon Chemiphar Co., Ltd. (JP) 2024-08-07 EP claimed
CN-118176003-A Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain 日本化学药品株式会社 2024-06-11 CN claimed
CN-118019551-A Preventive or therapeutic agent for respiratory diseases 日本化学药品株式会社 2024-05-10 CN claimed
WO-2023052518-A1 MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) 2023-04-06 WO claimed
WO-2023054578-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR RESPIRATORY DISEASES 日本ケミファ株式会社 2023-04-06 WO claimed
EP-4129296-A1 DRUG FOR PREVENTION OR TREATMENT OF IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE Università di Pisa (IT) 2023-02-08 EP claimed
US-11434207-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2022-09-06 US claimed
EP-3848051-A1 MEDICINE FOR DIABETIC PERIPHERAL NEUROPATHY Nippon Chemiphar Co., Ltd. (JP) 2021-07-14 EP claimed
US-20210121478-A1 MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS NIPPON CHEMIPHAR CO., LTD. (JP) 2021-04-29 US claimed
CN-111902146-A Medicinal product for treating cough 日本化学药品株式会社 2020-11-06 CN claimed
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2020-07-16 US claimed
EP-2803662-B1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO (JP) 2017-03-01 EP claimed
US-9382236-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2016-07-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250375456-A1 AGENT FOR PREVENTING OR TREATING RESPIRATORY DISEASE P2RX5, P2RX3, P2RX2 P2RX4 7/4885MAPT 4612/4885ALDH1A1 1763/4885
US-20210121478-A1 MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS TRPM4, TRPM7, P2RX3 P2RX4 5/4885MAPT 1093/4885ALDH1A1 2329/4885
US-20200223806-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 P2RX4 6/4885MAPT 4724/4885ALDH1A1 3019/4885
US-11434207-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 P2RX4 6/4885MAPT 4724/4885ALDH1A1 3019/4885
US-20260000678-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION TRPV1, TRPV4, TRPV5 P2RX4 15/4885MAPT 1187/4885ALDH1A1 3605/4885
US-20250241927-A1 MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN P2RX3, TRPV1, P2RX2 P2RX4 5/4885MAPT 3834/4885ALDH1A1 1661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.